Norrett Kevin 4

What Happened Kevin Norrett, Chief Business Officer of Soleno Therapeutics (SLNO), was granted a total of 7,500 restricted stock units (RSUs) on January 21, 2026. The filing shows two awards: 3,500 RSUs and 4,000 RSUs, each recorded with an acquisition price of $0.00 (these are compensation awards, not open-market purchases). The RSUs represent contingent rights to receive common shares if vesting conditions are met.

Key Details

• Transaction date: January 21, 2026; Form 4 filed January 23, 2026 (timely within the 2-business-day window).
• Awards: 3,500 RSUs (F1) and 4,000 RSUs (F2) — total 7,500 RSUs; acquisition price reported $0.00.
• Vesting notes: F1 — 100% of those RSUs vest on December 15, 2027, subject to continued service. F2 — RSUs subject to the applicable vesting schedule and conditions for each grant. F3 appears in the filing describing a separate option vesting schedule (1/48th monthly) but is not tied to these RSU grants.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Transaction code: A (award/grant). No sale or purchase of cash shares reported.

Context RSU grants are a form of compensation and do not require an out-of-pocket purchase; the reported $0.00 reflects that they were awarded. These awards are contingent — they only convert into actual shares if the specified vesting conditions (and continued service) are met, and they can dilute existing shareholders if and when they vest. This filing is informational and does not, by itself, indicate buying or selling interest in the open market.